199 related articles for article (PubMed ID: 22335611)
21. Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Asatiani E; Kessler CM;
Haemophilia; 2007 Nov; 13(6):685-96. PubMed ID: 17973844
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
24. Potential misdiagnosis of von Willebrand disease and haemophilia caused by ineffective mixing of thawed plasma.
Favaloro EJ; Oliver S; Mohammed S; Ahuja M; Grzechnik E; Azimulla S; McDonald J; Lima-Oliveira G; Lippi G
Haemophilia; 2017 Sep; 23(5):e436-e443. PubMed ID: 28750474
[TBL] [Abstract][Full Text] [Related]
25. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Aledort LM
J Thromb Haemost; 2004 Oct; 2(10):1700-8. PubMed ID: 15456478
[TBL] [Abstract][Full Text] [Related]
26. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion of coagulation factor concentrates during intensive treatment.
Holme PA; Tjønnfjord GE; Batorova A
Haemophilia; 2018 Jan; 24(1):24-32. PubMed ID: 28873263
[TBL] [Abstract][Full Text] [Related]
28. Congenital bleeding disorders. Rational treatment options.
Seremetis SV; Aledort LM
Drugs; 1993 Apr; 45(4):541-7. PubMed ID: 7684674
[TBL] [Abstract][Full Text] [Related]
29. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
Keularts IM; Hamulyak K; Hemker HC; Béguin S
Thromb Haemost; 2000 Oct; 84(4):638-42. PubMed ID: 11057863
[TBL] [Abstract][Full Text] [Related]
30. Translating the success of prophylaxis in haemophilia to von Willebrand disease.
Miesbach W; Berntorp E
Thromb Res; 2021 Mar; 199():67-74. PubMed ID: 33445035
[TBL] [Abstract][Full Text] [Related]
31. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.
Kouides P; Wawra-Hehenberger K; Sajan A; Mead H; Simon T
Transfusion; 2017 Oct; 57(10):2390-2403. PubMed ID: 28691218
[TBL] [Abstract][Full Text] [Related]
32. The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review.
Biere-Rafi S; Zwiers M; Peters M; van der Meer J; Rosendaal FR; Büller HR; Kamphuisen PW
Neth J Med; 2010 May; 68(5):207-14. PubMed ID: 20508269
[TBL] [Abstract][Full Text] [Related]
33. Haemate P/Humate-P: a systematic review.
Berntorp E
Thromb Res; 2009 Nov; 124 Suppl 1():S11-4. PubMed ID: 19944255
[TBL] [Abstract][Full Text] [Related]
34. FEIBA safety profile in multiple modes of clinical and home-therapy application.
Luu H; Ewenstein B
Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
[TBL] [Abstract][Full Text] [Related]
35. Inhibitor development in non-severe haemophilia across Europe.
Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
[TBL] [Abstract][Full Text] [Related]
36. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
38. Continuous infusion therapy in haemophilia.
Varon D; Martinowitz U
Haemophilia; 1998 Jul; 4(4):431-5. PubMed ID: 9873771
[TBL] [Abstract][Full Text] [Related]
39. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
Rodeghiero F; Castaman G; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
[TBL] [Abstract][Full Text] [Related]
40. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
